ORAMED PHARMACEUTICALS INC (ORMP) Fundamental Analysis & Valuation

NASDAQ:ORMP • US68403P2039

3.38 USD
-0.02 (-0.59%)
At close: Mar 12, 2026
3.38 USD
0 (0%)
After Hours: 3/12/2026, 4:30:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ORMP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to ORMP. ORMP was compared to 193 industry peers in the Pharmaceuticals industry. While ORMP has a great health rating, there are worries on its profitability. ORMP has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. ORMP Profitability Analysis

1.1 Basic Checks

  • ORMP had positive earnings in the past year.
  • In the past year ORMP has reported a negative cash flow from operations.
  • In the past 5 years ORMP reported 4 times negative net income.
  • In the past 5 years ORMP always reported negative operating cash flow.
ORMP Yearly Net Income VS EBIT VS OCF VS FCFORMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

  • ORMP's Return On Assets of 19.89% is amongst the best of the industry. ORMP outperforms 97.93% of its industry peers.
  • ORMP's Return On Equity of 21.57% is amongst the best of the industry. ORMP outperforms 91.71% of its industry peers.
Industry RankSector Rank
ROA 19.89%
ROE 21.57%
ROIC N/A
ROA(3y)-10.8%
ROA(5y)-15.12%
ROE(3y)-11.25%
ROE(5y)-17.59%
ROIC(3y)N/A
ROIC(5y)N/A
ORMP Yearly ROA, ROE, ROICORMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

  • ORMP has a Profit Margin of 2192.60%. This is amongst the best in the industry. ORMP outperforms 99.48% of its industry peers.
  • ORMP does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 2192.6%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORMP Yearly Profit, Operating, Gross MarginsORMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. ORMP Health Analysis

2.1 Basic Checks

  • ORMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ORMP has less shares outstanding
  • Compared to 5 years ago, ORMP has more shares outstanding
  • There is no outstanding debt for ORMP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ORMP Yearly Shares OutstandingORMP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ORMP Yearly Total Debt VS Total AssetsORMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • ORMP has an Altman-Z score of 4.46. This indicates that ORMP is financially healthy and has little risk of bankruptcy at the moment.
  • ORMP has a Altman-Z score of 4.46. This is in the better half of the industry: ORMP outperforms 74.09% of its industry peers.
  • ORMP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.46
ROIC/WACCN/A
WACC8.88%
ORMP Yearly LT Debt VS Equity VS FCFORMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 22.24 indicates that ORMP has no problem at all paying its short term obligations.
  • ORMP's Current ratio of 22.24 is amongst the best of the industry. ORMP outperforms 92.23% of its industry peers.
  • ORMP has a Quick Ratio of 22.24. This indicates that ORMP is financially healthy and has no problem in meeting its short term obligations.
  • ORMP has a better Quick ratio (22.24) than 92.23% of its industry peers.
Industry RankSector Rank
Current Ratio 22.24
Quick Ratio 22.24
ORMP Yearly Current Assets VS Current LiabilitesORMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ORMP Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 726.67% over the past year.
  • ORMP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)726.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ORMP is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -30.19% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y825.33%
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%
EPS Next 5Y-30.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORMP Yearly Revenue VS EstimatesORMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2025 500K 1M 1.5M 2M 2.5M
ORMP Yearly EPS VS EstimatesORMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

4

4. ORMP Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 2.73, the valuation of ORMP can be described as very cheap.
  • 97.93% of the companies in the same industry are more expensive than ORMP, based on the Price/Earnings ratio.
  • ORMP's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.15.
  • ORMP is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 2.73
Fwd PE N/A
ORMP Price Earnings VS Forward Price EarningsORMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORMP Per share dataORMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A cheap valuation may be justified as ORMP's earnings are expected to decrease with -66.87% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. ORMP Dividend Analysis

5.1 Amount

  • ORMP has a Yearly Dividend Yield of 7.61%, which is a nice return.
  • ORMP's Dividend Yield is rather good when compared to the industry average which is at 0.71. ORMP pays more dividend than 98.45% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, ORMP pays a better dividend.
Industry RankSector Rank
Dividend Yield 7.61%

5.2 History

  • ORMP does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
ORMP Yearly Dividends per shareORMP Yearly Dividends per shareYearly Dividends per share 2026 0.05 0.1 0.15 0.2

5.3 Sustainability

DPN/A
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%
ORMP Yearly Income VS Free CF VS DividendORMP Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

More info and screens

Find the best dividend stocksShow peers with best dividend

ORMP Fundamentals: All Metrics, Ratios and Statistics

ORAMED PHARMACEUTICALS INC

NASDAQ:ORMP (3/12/2026, 4:30:02 PM)

After market: 3.38 0 (0%)

3.38

-0.02 (-0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-08
Earnings (Next)03-25
Inst Owners27.78%
Inst Owner Change49.57%
Ins Owners15.95%
Ins Owner Change15.95%
Market Cap134.52M
Revenue(TTM)2.00M
Net Income(TTM)43.85M
Analysts43.33
Price TargetN/A
Short Float %1.67%
Short Ratio2.37
Dividend
Industry RankSector Rank
Dividend Yield 7.61%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date01-16
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1852.45%
Min EPS beat(2)859.8%
Max EPS beat(2)2845.1%
EPS beat(4)3
Avg EPS beat(4)510.54%
Min EPS beat(4)-1762.75%
Max EPS beat(4)2845.1%
EPS beat(8)6
Avg EPS beat(8)-569.36%
EPS beat(12)10
Avg EPS beat(12)-366.78%
EPS beat(16)11
Avg EPS beat(16)-276.91%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.78%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 2.73
Fwd PE N/A
P/S 67.26
P/FCF N/A
P/OCF N/A
P/B 0.66
P/tB 0.66
EV/EBITDA N/A
EPS(TTM)1.24
EY36.69%
EPS(NY)-1.29
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0.05
BVpS5.11
TBVpS5.11
PEG (NY)0
PEG (5Y)N/A
Graham Number11.94
Profitability
Industry RankSector Rank
ROA 19.89%
ROE 21.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 2192.6%
GM N/A
FCFM N/A
ROA(3y)-10.8%
ROA(5y)-15.12%
ROE(3y)-11.25%
ROE(5y)-17.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.75%
Cap/Sales 0.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.24
Quick Ratio 22.24
Altman-Z 4.46
F-Score5
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)324.08%
Cap/Depr(5y)449.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)726.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
EPS Next Y825.33%
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%
EPS Next 5Y-30.19%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.49%
OCF growth 3YN/A
OCF growth 5YN/A

ORAMED PHARMACEUTICALS INC / ORMP FAQ

What is the fundamental rating for ORMP stock?

ChartMill assigns a fundamental rating of 5 / 10 to ORMP.


What is the valuation status for ORMP stock?

ChartMill assigns a valuation rating of 4 / 10 to ORAMED PHARMACEUTICALS INC (ORMP). This can be considered as Fairly Valued.


How profitable is ORAMED PHARMACEUTICALS INC (ORMP) stock?

ORAMED PHARMACEUTICALS INC (ORMP) has a profitability rating of 3 / 10.


What are the PE and PB ratios of ORAMED PHARMACEUTICALS INC (ORMP) stock?

The Price/Earnings (PE) ratio for ORAMED PHARMACEUTICALS INC (ORMP) is 2.73 and the Price/Book (PB) ratio is 0.66.


How financially healthy is ORAMED PHARMACEUTICALS INC?

The financial health rating of ORAMED PHARMACEUTICALS INC (ORMP) is 9 / 10.